United Therapeutics controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2020
United Therapeutics sues Liquidia over Tyvaso patents
Lawsuit filed
United Therapeutics filed a lawsuit in a U.S. district court against Liquidia, alleging infringement of patents relating to its Tyvaso product. The suit followed Liquidia's application seeking FDA approval to market LIQ861; the source reports no court determination on the allegations.
Source excerpt
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Liquidia Technologies, Inc. (Liquidia) for infringement of the following patents relating to United Therapeutics' product Tyvaso® (treprostinil) Inhalation Solution: U.S. Patent Nos. 9,604,901 (the '901 patent) and 9,593,066 (the '066 patent), both of which expire in December 2028.
The lawsuit is based on a New Drug Application (NDA) filed by Liquidia with the U.S. Food and Drug Administration (FDA) requesting approval to market LIQ861, a dry powder inhalation formulation of treprostinil.